Peptide epitope identification for tumor-reactive CD4 T cells

https://doi.org/10.1016/j.coi.2008.04.011Get rights and content

Because T lymphocytes have the capacity to recognize tumor cells, significant efforts are being devoted towards the development of T cell-based immunotherapy for cancer. Most of this work has centered in the induction of anti-tumor CD8 T cells, which exhibit cytolytic activity towards tumor cells expressing tumor-specific or tumor associated antigens. Unfortunately to this day, T cell-based immunotherapy for cancer remains suboptimal. One of the possible explanations is that these immunotherapies have ignored the role that CD4 T helper lymphocytes play in the generation and persistence of CD8 T cell responses. Thus, we believe that in order to obtain clinical benefits T cell-based immunotherapy must stimulate both CD8 and CD4 tumor-reactive T cell responses. During the past seven years our group has focused on the identification of CD4 T cell epitopes from tumor-associated and tumor-specific antigens that could be used to complement the already identified CD8 T cell epitopes to produce effective vaccination strategies against numerous tumor types. We will describe here the strategy we used that resulted in the identification and characterization of numerous CD4 T cell epitopes that are applicable to developing therapies against hematological malignancies and solid tumors.

Introduction

Most immune therapy approaches to combat malignant diseases have centered in the induction of CD8 T cell responses against tumor-associated antigens mainly because these cells can be very effective in killing tumor cells. The two most commonly thought therapeutic approaches based on the use of anti-tumor CD8 cytotoxic T lymphocytes (CTLs) are the use of various types of vaccines that generate in vivo immune responses (active immunotherapy) or the infusion of in vitro expanded CTLs (adoptive T cell therapy) [1]. Although CTLs have been considered to be the main protagonists in the production of anti-tumor therapeutic effects resulting from vaccines or adoptive T cell therapy, it is clear that CD4 helper T lymphocytes (HTLs) can also participate in the generation of anti-tumor responses through various mechanisms [2, 3]. On one hand, HTLs are critical for the generation and persistence of CTL responses by providing help through multiple interactions with antigen-presenting cells and CD8 T cells during the induction of the immune responses in secondary lymphoid organs [4, 5, 6]. Later on, HTLs continue to sustain CTL responses through the maintenance of memory cells in the periphery or by directly providing costimulatory signals to the CTL, which enhance their function and survival at the tumor site [7, 8, 9••]. In addition, tumor-infiltrating HTLs may function as effector cells either by the local production of cytokines that curtail tumor growth or in some instances by exhibiting anti-tumor cytotoxic activity [10, 11]. Because CD4 HTLs recognize antigen as peptide epitopes presented in the context of MHC class II molecules (MHC-II), the effector activity of these cells will be circumscribed to those tumor cells that express MHC class II molecules or in those instances where conventional antigen-presenting cells (e.g. macrophages, dendritic cells) are able to capture, process and present antigens derived from tumor cells to the HTLs. In view of the above, there has been a considerable interest in identifying MHC-II epitopes for tumor-reactive HTL with the purpose of using this information to develop more effective forms of immunotherapy against malignant diseases.

The identification of sequence motifs in peptides capable of binding to MHC-II molecules of various alleles has lead to the development of computer-based algorithms to predict the existence of CD4 T cell epitopes within the amino acid sequence of a putative tumor-associated antigen (TAA) [12, 13, 14]. In many instances these algorithms have been validated and further refined using quantitative peptide/MHC-II binding assays. We have extensively used one of such algorithms that was designed to identify peptide binders to the products of three commonly found human MHC-II alleles: HLA-DR1, DR4 and DR7 [13]. In our studies, we tried to select peptide sequences that scored high in the probability scale for their binding capacity for all three MHC-II alleles with the goal of identifying promiscuous CD4 T cell epitopes that would result a broad population coverage for a specific clinical indication. The strategy to identify promiscuous CD4 T cell epitopes using the predictive approach would follow these steps:

  • (a)

    Selection of the protein antigen

    There are several characteristics that would make a particular protein interesting and suitable for the analysis. The most obvious one is that the complete amino acid sequence of the target antigen must be known. Second, it is advisable to select large proteins instead of smaller ones since the probability of finding one or more potential MHC class II binding epitopes will increase. Another desirable characteristic of the protein antigen would be to select antigens that are only expressed by tumor cells and not normal cells. The reasons are that immune tolerance mechanisms operating against self-proteins will reduce the effectiveness of immune responses against tumors. In addition, in the event that strong immune responses were to be induced against a self-antigen, there would be a significant risk of autoimmune pathology towards normal tissues expressing that antigen. Unfortunately, these ‘tumor-specific antigens’ (TSA) are not frequently encountered, so in many cases one has to rely in the use of ‘tumor-associated antigens (TAA) [15]. However, examples of TSA are proteins derived from oncogenic viruses that continue to be expressed by the malignant cells or products of mutated/rearranged genes that are specifically expressed by the tumor cells [16, 17]. Some TAA that are desirable candidates for immunotherapy are those that belong to the ‘Cancer Testes’ (CT) family [18]. These products are expressed in tumor cells and in germinal cells, but not in most normal tissues, limiting the deleterious effects of tolerance and autoimmunity. Other TAA candidates have limited expression in some tissues that are considered not to be vital (prostate, breast, melanocytes). Thus, depending on the tumor type, one may have a single or multiple protein candidates to chose from to submit for prediction analysis for the presence of MHC-II binding peptides.

  • (b)

    Prediction algorithms for CD4 T cell epitopes

    Originally these algorithms were based on the presence of specific residues (or type of residues: hydrophobic, positive/negative charged) present at particular positions within a short peptide sequence (9–15 residues long) that were found on T cell epitopes that had been mapped using antigen-specific T cell lines/clones. These motifs were found to be somewhat specific for individual MHC-II alleles but could not be clearly defined. In the case of MHC class I (MHC-I) binding peptides, it became feasible to identify more exact motifs by sequencing peptides eluted from purified MHC molecules because of their restricted size (8–10 residues). On the other hand peptides that bind to MHC-II do not have a constrained size (9–20 residues), making sequencing analysis interpretation much more difficult. A major breakthrough in the design of MHC-II binding algorithms was the development of quantitative MHC-II peptide binding assays. Using this approach, Southwood and collaborators constructed a computer-based algorithm based on a large database of MHC-II binding peptides [13]. This database keeps being refined [19] and the respective algorithms to predict probability of peptides to bind to diverse human (and mouse) MHC-II alleles have been made available to researchers through the Internet (http://www.immuneepitope.org/). We have utilized this algorithm in numerous occasions to predict the existence of peptide sequences from TSA and TAA capable of binding to three frequently found MHC-II alleles (HLA-DR1, DR4 and DR7). Results obtained from these algorithms are utilized to limit the number of synthetic peptides that will be tested for their ability to induce T cell responses in labor-intensive cell cultures.

  • (c)

    In vitro immunization of human lymphocytes using candidate CD4 T cell epitopes

    Once a manageable number of peptide sequences have been selected from the algorithm analysis, synthetic peptides are made and tested in tissue culture for their ability to stimulate CD4 T cell responses. The technique to generate antigen-specific CD4 T cell lines and clones used by our group has been described in detail [20]. Briefly, the in vitro immunization method utilizes purified CD4 T cells isolated from peripheral blood of normal volunteers that are stimulated using peptide-pulsed autologous dendritic cells (DCs). The cultures are restimulated periodically with autologous irradiated periheral blood mononuclear cells in the presence of IL-2. T cell lines and clones (isolated by limiting dilution) are then submitted to MHC restriction analysis using HLA-typed antigen-presenting cells (APCs) and mouse fibroblast cells (L-cells) transfected with individual human MHC-II alleles. Peptide-titration curves can be done to estimate the antigen avidity of the T cells. The most important step in this process is to assess whether the peptide-reactive CD4 T cell lines (or clones) have the capacity to recognize the TSA or TAA derived from tumor cells. Only with this validation one can be assured that the peptide in question represents a true tumor-specific CD4 T cell epitope. We believe that this validation is necessary before even considering using the peptide as a vaccine or peptide-reactive T cells for adoptive immunotherapy.

  • (d)

    Assessing tumor-reactivity of peptide-reactive CD4 T cells

Two types of assays can be done to demonstrate that synthetic peptides capable of eliciting CD4 T cell responses represent real tumor-specific (or tumor-associated) epitopes. The first one is to determine the ability of a CD4 T cell line to recognize antigen presented directly by the tumor cells. For this to take place, one must utilize tumor cell lines that express MHC-II surface molecules, as it occurs with many hematological malignancies (e.g. B and T cell lymphomas). In the case of cell lines derived from solid tumors, expression of MHC-II molecules may be induced by treating the cells for 24–74 hours with interferon-gamma (IFNγ), before performing the immunological assays. One limiting factor with this type of assay is that the tumor cells must express the same MHC-II allele that restricts the response of the CD4 T cells to peptide. In the second type of assay one estimates the capacity of autologous DCs to capture, process and present tumor antigen proteins. In some instances one may use purified recombinant DNA-produced tumor antigen if it is available. In most cases it is possible to feed the DCs with tumor cell lysates (freeze-thaw) or apoptotic (UV light-induced) tumor cells. Under these circumstances, the tumor cell lines do not require to express MHC-II molecules because the CD4 T cells will recognize the processed epitope in the context of the DC's MHC-II molecules. Antigen specificity is validated by using control tumor cell lines that do not express the tumor antigen in question and by the demonstration that antibodies to MHC-II molecules can block the reactivity of the CD4 T cells recognizing the antigen presented by the DCs. We strongly argue that only by fulfilling the above-mentioned criteria one can be certain that the peptide epitope originally identified as an MHC-II-binding candidate truly represents a tumor-specific epitope for CD4 T cells. Without this demonstration it would be unwise and perhaps unethical to proceed with clinical development to use a CD4 T cell epitope in cancer patients.

Our studies have focused on two viruses responsible for hematological malignancies in humans, Epstein-Barr virus (EBV) and human T-cell leukemia virus-1 (HTLV-1). For these studies, we selected viral protein antigens that continue to be expressed in the malignant cells and that in most instances are involved in the establishment of the malignant phenotype. EBV is responsible for post-transplant lymphoproliferative disease in immunosuppressed individuals that can progress to B-cell lymphomas, and for other malignancies such as NK/T cell lymphoma and several lymphoepithelioma-like carcinomas including nasopharyngeal carcinoma (NPC) and gastric carcinoma. Our studies have identified CD4 T cell epitopes from two viral latent cycle antigens, EBNA2 and LMP1 that could be presented in the context of several MHC-II alleles (Table 1) [21, 22]. The reactivity of the peptide induced CD4 T cell lines and clones was significant against various EBV-transformed cells (examples presented in Figure 1). Other studies from our group helped identify CD4 T cell epitopes from two antigens expressed by HTLV-1 (the causative agent of adult T cell leukemia/lymphoma), the Tax and the envelope antigens (Table 1) [23, 24•]. Again, an important feature of the peptide-induced CD4 T cells was their ability to react with HTLV-1 expressing tumor cells (Figure 1).

Our studies have focused in the identification of CD4 T cell epitopes for tumor types that affect large number of individuals throughout the world, such as breast, prostate, gastrointestinal cancers and malignant melanoma. Proteins that function as TAA because they are either differentiation (tissue-specific) antigens (gp100, PSMA, TARP, STEAP), tumor markers (CEA, HER2/neu, WT1) or belong to the family of cancer-testes antigens (MAGE-A3) were studied as potential sources for CD4 T cell epitopes. Our studies following the strategy described above resulted in the identification of several novel CD4 T cell epitopes for these antigens (Table 1) [20, 25, 26, 27, 28, 29, 30, 31, 32•]. As mentioned previously, the most critical issue is to demonstrate the reactivity of peptide-induced CD4 T cells against tumor cells that express MHC-II and the TAA or alternatively, towards autologous DCs that are fed with antigens derived from tumor cells (e.g. freeze-thaw lysates). The examples presented in Figure 2 illustrate how effective was the ability of various CD4 T cell lines induced with peptides selected from MHC-II binding predictive algorithms, to recognize antigens derived from tumor cells.

Throughout our studies, we observed that many of the CD4 T cell epitopes that we identified contain within their sequence, or lie proximal to previously described CD8 T cell epitopes (Table 1) [33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46•, 47•]. Although we do not know whether the close proximity between CD4 and CD8 T cell epitopes is simply a coincidence or holds a biological significance, this observation opens the possibility of using synthetic peptides of relatively small size (15–20 residues) to stimulate CD4 and CD8 T cell responses simultaneously [47•, 48, 49, 50•]. In addition, it has been proposed that large peptides containing MHC-II binding domains may be an effective way to deliver antigens to professional APCs to generate more effective immune responses [51••].

Section snippets

Closing remarks

The identification of CD4 T cell epitopes for tumor antigens has attracted a high degree of interest because of the belief that immune based therapies against cancer will be more effective if both CD8 and CD4 T lymphocytes participate in curtailing tumor cell growth. CD4 T cells not only are capable of enhancing CD8 T cell responses but may also exhibit anti-tumor effector function. Although many studies in animal models have clearly demonstrated better results when both CD4 and CD8 T cells

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

  • • of special interest

  • •• of outstanding interest

Acknowledgements

This work was supported by NIH grants P50CA91956, R01CA80782 and R01CA103921 (E. Celis) and Ministry of Education, Sports, and Culture of Japan grant-in-aid 18590360 (H. Kobayashi).

References (55)

  • B. Rocha et al.

    Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses

    Curr Opin Immunol

    (2004)
  • N. Harashima et al.

    Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation

    Cancer Res

    (2004)
  • J.A. Berzofsky et al.

    Progress on new vaccine strategies for the immunotherapy and prevention of cancer

    J Clin Invest

    (2004)
  • K. Hung et al.

    The central role of CD4(+) T cells in the antitumor immune response

    J Exp Med

    (1998)
  • C.M. Smith et al.

    Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity

    Nat Immunol

    (2004)
  • C. Bourgeois et al.

    A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory

    Science

    (2002)
  • E.M. Janssen et al.

    CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

    Nature

    (2003)
  • R.L. Giuntoli et al.

    Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function

    Clin Cancer Res

    (2002)
  • R. Kennedy et al.

    Direct cross-priming by Th lymphocytes generates memory cytotoxic T cell responses

    J Immunol

    (2005)
  • R. Kennedy et al.

    T helper lymphocytes rescue CTL from activation-induced cell death

    J Immunol

    (2006)
  • S. Hahn et al.

    Mechanism and biological significance of CD4-mediated cytotoxicity

    Immunol Rev

    (1995)
  • T.A. Haigh et al.

    EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines

    J Immunol

    (2008)
  • T. Sturniolo et al.

    Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices

    Nat Biotechnol

    (1999)
  • S. Southwood et al.

    Several common HLA-DR types share largely overlapping peptide binding repertoires

    J Immunol

    (1998)
  • H. Rammensee et al.

    SYFPEITHI: database for MHC ligands and peptide motifs

    Immunogenetics

    (1999)
  • L. Novellino et al.

    A listing of human tumor antigens recognized by T cells: March 2004 update

    Cancer Immunol Immunother

    (2005)
  • R.F. Wang et al.

    Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

    Science

    (1999)
  • B.S. Worley et al.

    Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations

    Cancer Res

    (2001)
  • E. Jager et al.

    Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

    J Exp Med

    (1998)
  • H.H. Bui et al.

    Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications

    Immunogenetics

    (2005)
  • H. Kobayashi et al.

    Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen

    Cancer Res

    (2000)
  • R. Omiya et al.

    Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope

    J Immunol

    (2002)
  • H. Kobayashi et al.

    Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells

    Cancer Res

    (2008)
  • H. Kobayashi et al.

    Recognition of adult T-cell leukemia/lymphoma cells by CD4+ helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein

    Clin Cancer Res

    (2004)
  • H. Kobayashi et al.

    In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes

    Clin Cancer Res

    (2006)
  • H. Kobayashi et al.

    Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen

    Cancer Res

    (2001)
  • H. Kobayashi et al.

    Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles

    Cancer Res

    (2001)
  • Cited by (42)

    • Cancer immunotherapy: moving forward with peptide T cell vaccines

      2017, Current Opinion in Immunology
      Citation Excerpt :

      In many instances HTLs are effective in killing MHC class II (MHC-II) expressing tumor cells [36], but in other cases, HTLs can eradicate MHC-II negative tumor cells [37•]. Our group has been involved in identifying MHC-II binding peptides from numerous human tumor antigens capable of functioning as HTL epitopes [19•]. Many of these peptides function as promiscuous epitopes (can be presented by several MHC-II alleles), potentially allowing their use as vaccines in broad patient populations.

    • CD4 T Cells in Antitumor Immunity

      2016, Encyclopedia of Immunobiology
    • Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine

      2014, Immunology Letters
      Citation Excerpt :

      This may be because of the existence of strong immunosuppression, tumor escape mechanisms and/or the lack of helper T cell activation [5,32–35]. We previously demonstrated a critical role for Th1 and Th2 immunity in tumor-bearing hosts and proposed that the introduction of Th1-dominant immunity is essential for inducing fully activated CTL and immunological memory [5,36,37]. Moreover, we demonstrated that Th1-dominant immunity could suppress the accumulation of immunosuppressive Treg cells into the tumor local site in an IFN-γ-dependent manner [38].

    • Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells

      2014, Immunology Letters
      Citation Excerpt :

      It has been demonstrated that cancer vaccine therapy using the HLA class I-binding short peptide derived from the CT antigen caused an increase of tetramer-positive cytotoxic T lymphocytes (CTLs) in cancer patients and maintained the patients at long stable disease. However, we have proposed that Th1-dominant immunity in a tumor-bearing host was essential for the induction of fully activated CTLs and the subsequent generation of memory T cells [11–16]. Recently, it has been reported that the human papillomavirus (HPV)-16-derived long peptide, containing both helper and killer epitopes, remarkably eradicated established HPV-16-expressing tumors [17].

    • Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: A biotech's challenge

      2012, Biotechnology Advances
      Citation Excerpt :

      Given the critical role played by CD4+ T cells in determining the functional status and memory of effector cell response, the inclusion of appropriate CD4+ T cell epitopes may be essential for vaccine efficacy. Thus, both identification of peptide epitopes for tumor-reactive CD4+ T cells (Kobayashi and Celis, 2008) and rational selection of promiscuous CD4+ epitopes for inclusion in vaccine formulation are crucial for successful application of antitumor vaccination strategy (Rosa et al., 2010). T cell epitope mapping allows identifying peptide sequences that are recognized by CD8+ or CD4+ T cells on antigenic proteins.

    • A simple competitive assay to determine peptide affinity for HLA class II molecules: A useful tool for epitope prediction

      2011, Journal of Immunological Methods
      Citation Excerpt :

      It is now well accepted that vaccination strategies with peptides in infectious diseases and cancer should activate both CD4 and CD8 responses to be efficient (Wang and Livingstone, 2003; Kobayashi and Celis, 2008; Melief and van der Burg, 2008).

    View all citing articles on Scopus
    View full text